Barclays Portfolio holdings
Barclays PLC, founded in 1690 by goldsmith bankers in London, is a British multinational financial institution headquartered in London, operating as one of the world’s oldest banks with a significant presence in investment banking, retail banking, and wealth management. Managing billions in assets, Barclays serves millions of customers globally through its retail arm (notably in the UK) and its investment banking division, which excels in trading, mergers and acquisitions, and capital markets, competing with Wall Street giants. The bank has navigated challenges like the 2008 financial crisis—opting for private funding over a government bailout—and has since focused on restructuring, digital innovation, and sustainable finance initiatives. With a rich history and a modern global footprint, Barclays remains a key player in both UK and international financial markets.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$572M |
| 2 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$495M |
| 3 |
iShares MBS ETF
MBB
|
+$405M |
| 4 |
Procter & Gamble
PG
|
+$365M |
| 5 |
Microsoft
MSFT
|
+$327M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Invesco QQQ Trust
QQQ
|
+$605M |
| 2 |
iShares Russell 2000 ETF
IWM
|
+$544M |
| 3 |
Sempra
SRE
|
+$474M |
| 4 |
CELG
Celgene Corp
CELG
|
+$411M |
| 5 |
BPL
Buckeye Partners, L.P.
BPL
|
+$380M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 8.85% |
| 2 | Healthcare | 5.77% |
| 3 | Financials | 5.26% |
| 4 | Consumer Discretionary | 4.71% |
| 5 | Communication Services | 4.69% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
NBEV
5051
DELISTED
NewAge, Inc. Common Stock (Delaware)
NBEV
| $174K | ﹤0.01% |
95,730
-53,842
| -36% | -$127K |
|
|
GMLP
5052
DELISTED
Golar LNG Partners LP
GMLP
| $174K | ﹤0.01% |
19,777
+1,456
| +8% | +$13.8K |
|
5053
PUT
Olin
OLN
$2.11B
| $173K | ﹤0.01% |
10,000
+8,400
| +525% | +$150K |
|
5054
Stantec
STN
$8.04B
| $173K | ﹤0.01% |
6,100
+3,400
| +126% | +$84.1K |
|
|
PVLA
5055
Palvella Therapeutics
PVLA
$1.99B
| $173K | ﹤0.01% |
600
-21
| -3% | -$5.82K |
|
|
SLCA
5056
PUT
DELISTED
U.S. SILICA HOLDINGS, INC.
SLCA
| $173K | ﹤0.01% |
28,200
-34,000
| -55% | -$205K |
|
|
CHS
5057
CALL
DELISTED
Chicos FAS, Inc.
CHS
| $173K | ﹤0.01% |
45,400
+30,100
| +197% | +$116K |
|
5058
PUT
Compañía de Minas Buenaventura
BVN
$7.69B
| $172K | ﹤0.01% |
+11,400
| New | +$169K |
|
5059
PUT
Cemex
CX
$17.1B
| $172K | ﹤0.01% |
45,400
-5,300
| -10% | -$20.2K |
|
5060
CALL
Designer Brands
DBI
$307M
| $172K | ﹤0.01% |
10,900
+1,300
| +14% | +$21.5K |
|
5061
CALL
ING
ING
$99.8B
| $172K | ﹤0.01% |
14,300
-6,600
| -32% | -$75.6K |
|
|
GPX
5062
DELISTED
GP Strategies Corp.
GPX
| $172K | ﹤0.01% |
13,036
+6,247
| +92% | +$77.5K |
|
5063
iRadimed
IRMD
$1.16B
| $171K | ﹤0.01% |
7,362
+2,010
| +38% | +$47K |
|
5064
CALL
Nasdaq
NDAQ
$52.7B
| $171K | ﹤0.01% |
4,800
-7,500
| -61% | -$256K |
|
|
LL
5065
PUT
DELISTED
LL Flooring Holdings, Inc.
LL
| $171K | ﹤0.01% |
17,500
-68,000
| -80% | -$636K |
|
|
CHMA
5066
DELISTED
Chiasma, Inc. Common Stock
CHMA
| $171K | ﹤0.01% |
34,353
+17,465
| +103% | +$90.9K |
|
5067
PUT
ADT
ADT
$5.58B
| $170K | ﹤0.01% |
+21,400
| New | +$169K |
|
5068
AXT Inc
AXTI
$3.95B
| $170K | ﹤0.01% |
39,289
+19,697
| +101% | +$63.2K |
|
5069
Alico
ALCO
$280M
| $169K | ﹤0.01% |
4,700
+2,064
| +78% | +$69.4K |
|
5070
PUT
ProShares VIX Short-Term Futures ETF
VIXY
$201M
| $169K | ﹤0.01% |
+170
| New | +$211K |
|
|
TCRR
5071
DELISTED
TCR2 Therapeutics Inc. Common Stock
TCRR
| $169K | ﹤0.01% |
11,885
+6,000
| +102% | +$92.8K |
|
5072
America Movil
AMX
$76.1B
| $168K | ﹤0.01% |
10,549
-34,268
| -76% | -$536K |
|
5073
PUT
Coca-Cola Europacific Partners
CCEP
$48.3B
| $168K | ﹤0.01% |
3,300
+3,100
| +1,550% | +$163K |
|
5074
Eastern Company
EML
$143M
| $168K | ﹤0.01% |
5,514
+2,534
| +85% | +$71K |
|
5075
Ocular Therapeutix
OCUL
$1.79B
| $168K | ﹤0.01% |
42,465
-13,732
| -24% | -$47.7K |
|
Similar funds
Barclays's Q4 2019 Portfolio in Review
As of Q4 2019, Barclays held 7,254 positions worth $180B, up 13% from $160B the previous quarter. Its ten largest holdings account for 26% of the portfolio.
Barclays deployed $6.1B of net new capital in Q4 2019, opening 260 new positions and adding to 3,541 existing holdings. Its largest new stake was Pacer iPath Gold ETNs: 1,000,000 shares worth $25.3M.
By sector, the portfolio is most concentrated in Technology at 8.9% of assets, up from 7.7% a quarter earlier, followed by Healthcare and Financials.
On the sell side, the largest reduction was Invesco QQQ Trust, an estimated $605M trimmed.
- Barclays's largest Q4 2019 buy was Pacer iPath Gold ETNs: 1,000,000 shares worth $25.3M.
- Barclays added most to Apple in Q4 2019, an estimated $572M increase.
- Barclays's biggest Q4 2019 reduction was Invesco QQQ Trust, cutting an estimated $605M.
- Barclays fully exited Celgene Corp in Q4 2019, selling an estimated $411M.
- Barclays's ten largest holdings make up 26% of its $180B portfolio in Q4 2019.
- Barclays opened 260 new positions and closed 700 in Q4 2019.
- Barclays's portfolio value rose 13% quarter-over-quarter to $180B.
Based on Barclays's 13F filing for Q4 2019, filed 10 Feb 2020.